S'abonner

A comprehensive evaluation of serum circCSPP1 as a novel diagnostic and prognostic biomarker for gastric cancer - 14/05/24

Doi : 10.1016/j.clinre.2024.102367 
Hengchuan Shi, Shan Kong
 Department of Laboratory Medicine, Geriatric Hospital of Nanjing Medical University: Jiangsu Province Geriatric Hospital, Nanjing 210009 Jiangsu, China 

Corresponding author.

Highlights

Serum circCSPP1 levels decreased significantly after surgical resection but increased after recurrence. High circCSPP1 expression was associated with poor survival rates.
The circCSPP1 expression level was significantly correlated with tumor size, T stage, lymph node metastasis, and TNM stage.
The AUC of serum circCSPP1 level was 0.834, with high sensitivity and specificity for discriminating patients with GC from healthy donors.
The combined diagnosis of circCSPP1, carcinoembryonic antigen, and carbohydrate antigen 19–9 achieved a superior AUC of 0.882, indicating the highest specificity.

Le texte complet de cet article est disponible en PDF.

Abstract

Purpose

Gastric cancer (GC) has high incidence and mortality due to its low early screening efficiency. Circular RNAs (CircRNAs) are a new class of non-coding RNAs which is closely related to GC. Nevertheless, the clinical application value of circRNAs in GC are largely unknown. Therefore, we studied the role of a novel circRNA named circCSPP1 in patients with GC.

Methods

CircRNA sequencing was performed to screen out the target molecule. Real-time fluorescent quantitative PCR (RT-qPCR) was utilized to detect the expression level of circCSPP1 in GC tissues, cells, and serum. Gel and Sanger sequencing were utilized to verify the ring structure of circCSPP1. RNase R enzyme digestion experiment and actinomycin D experiment were verifed the advantage of circCSPP1 as a diagnostic biomarker in patients with GC when that compared with linear RNA. The correlation between the expression level of serum circCSPP1 and clinicopathological data of GC patients was further analyzed. Receiver operating characteristic curve (ROC) and the area under ROC curve (AUC) were utilied to evaluate the diagnostic performance.

Results

CircCSPP1 has a circular structure which with resistance to RNA exonuclease digestion and long half-life compared with linear RNA. In our study, circCSPP1 was first found up-regulated in patients with GC. Serum circCSPP1 level was decreased significantly after surgical resection whereas increased after recurrence. High expression of circCSPP1 was associated with poor survival rates. The expression level of circCSPP1 was significantly correlated to tumor size, T stage, lymph node metastasis, and TNM stage. The AUC of serum circCSPP1 was 0.834, with high sensitivity and specificity in discriminating patients with GC from healthy donors. More importantly, the combined diagnosis of circCSPP1, CEA, and CA19–9 achieved the superior AUC of 0.882, with the highest specificity.

Conclusion

Serum circCSPP1 may prove to be a potential non-invasive auxiliary diagnostic biomarker for patients with GC.

Le texte complet de cet article est disponible en PDF.

Keywords : Biogenesis, Biomarker, CircCSPP1, Diagnosis, Gastric cancer

Abbreviations : GC, CircRNA, gDNA, cDNA, SEN, SPE, ACCU, PPV, NPV, AGE, CV, CI, RT-qPCR, ROC, AUC, CEA, CA19–9


Plan


© 2024  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 48 - N° 6

Article 102367- juin 2024 Retour au numéro
Article précédent Article précédent
  • The impact of secondhand smoke on failure of Helicobacter pylori therapy is not inferior to that of smoking
  • Jiajia Wu, Zheng Qian, Dingfu Zhong, Min Lin
| Article suivant Article suivant
  • The impact of WeChat online education and care on the mental distress of caregivers and satisfaction of elderly postoperative colorectal cancer patients
  • Hui Lu, Huihong Wang, Lingyun Zhu, Jiahui Xu, Zhenzhen Su, Wenxia Dong, Fen Ye

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.